LH

Labcorp and Providence Expand Strategic Laboratory Relationship

Retrieved on: 
화요일, 5월 16, 2023
Genomics, Organization, Pathology, LH, Health, Caregiver, Hospital, Patient, NYSE, Pharmaceutical industry, Labcorp

BURLINGTON, N.C., May 16, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations. Through the agreement, Labcorp will acquire Providence Oregon's outreach laboratory business and select assets in Oregon. Providence Oregon will maintain operation and ownership of certain anatomic pathology and genomics outreach testing and its hospital laboratories in the region.

Key Points: 
  • BURLINGTON, N.C., May 16, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations.
  • Through the agreement, Labcorp will acquire Providence Oregon's outreach laboratory business and select assets in Oregon.
  • This transaction will build on the more than 20-year relationship between Labcorp and the Providence family of organizations.
  • Labcorp currently provides laboratory services to several Providence affiliate medical facilities and reference testing for facilities across multiple states served by Providence in the western United States.

Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration

Retrieved on: 
수요일, 5월 3, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Partnership, Drug development, Gene, LH, AAV, Patient, Cell, Toxicology, NYSE, Pharmacology, Safety, Pharmaceutical industry, Forge, Labcorp

Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company.

Key Points: 
  • Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company.
  • As a result of this strategic collaboration, gene therapy clients across the industry will gain access to manufacturing capabilities, drug development services, and coordinated scientific expertise, creating greater accessibility to services for adeno-associated virus (AAV) mediated gene therapy programs.
  • Working together, Labcorp and Forge are positioned to accelerate clinical timelines, reduce analytical development constraints, and mitigate potential regulatory challenges related to manufacturing and development processes.
  • “Labcorp’s comprehensive gene therapy drug development capabilities and scientific expertise, combined with the full suite of AAV manufacturing capabilities from Forge, will enable us to enhance and accelerate the AAV gene therapy development experience for our customers.”
    Forge’s 20 cGMP suites make it one of the largest global AAV manufacturers.

LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP

Retrieved on: 
수요일, 5월 3, 2023
HLA, Transfusion medicine, Teaching, Thomas Jefferson University, Pathology, LH, Research, Jefferson Health, Patient, Flow cytometry, Autoimmune disease, IDEA, Health, Neurology, NYSE, Pharmaceutical industry, Nursing, MD, Labcorp

BURLINGTON, N.C., May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey. When complete, the arrangements between Jefferson and Labcorp will serve to build academic collaborations around teaching and the development of innovative tests.

Key Points: 
  • BURLINGTON, N.C., May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.
  • Jefferson and Labcorp will work together to establish the Innovation Driving Excellence in Academics (IDEA) initiative, with a goal of advancing testing capabilities and technologies to improve health outcomes.
  • "This strategic relationship enables Jefferson to leverage Labcorp's wide-range of laboratory services, which will help deliver improved outcomes for our patients and optimal service to providers," said Joseph G. Cacchione, MD, CEO, Jefferson.
  • This relationship follows other strategic collaborations that Labcorp has established with a range of local and regional health systems that have enhanced services for patients and providers.

Labcorp Announces 2023 First Quarter Results

Retrieved on: 
화요일, 4월 25, 2023
Capital expenditure, COVID-19 testing, Corporate social responsibility, Launch pad, COVID-19, Drug, LH, COVID, FSP, Public expenditure, Acquisition, Laboratory, Corporation, Capital, Council for the Central Laboratory of the Research Councils, Growth, Weather, EPS, NHP, Health, NYSE, PCR, Ascension, Management, Pharmaceutical industry, Video game, Public utility, Labcorp

BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Key Points: 
  • BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.
  • In the first quarter, Labcorp executed against its strategic plan to position the business for both short- and long-term growth.
  • Revenue for the quarter was $3.78 billion, a decrease of (3.1%) from $3.90 billion in the first quarter of 2022.
  • Labcorp is updating 2023 full year guidance to reflect its first quarter performance and full year outlook.

LABCORP DECLARES QUARTERLY DIVIDEND

Retrieved on: 
목요일, 4월 6, 2023
LH, NYSE, Holding company, Labcorp

BURLINGTON, N.C., April 6, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Key Points: 
  • BURLINGTON, N.C., April 6, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
  • The dividend will be payable on June 8, 2023, to stockholders of record as of the close of business on May 18, 2023.

LABCORP EXPANDS ACCESS TO COLORECTAL CANCER SCREENING THROUGH PARTNERSHIP WITH THE CONFERENCE OF NATIONAL BLACK CHURCHES

Retrieved on: 
월요일, 4월 3, 2023
Labcorp Drug Development, FIT, Health equity, Cancer, Quality of life, LH, Large intestine, Black, CDC, CNBC, Colorectal cancer, Incidence, Patient, Risk, Conditional sentence, FSA, American Cancer Society, HSA, Conference, NYSE, Disease, Health insurance, Medical imaging, Labcorp

BURLINGTON, N.C., April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches will distribute over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond.

Key Points: 
  • BURLINGTON, N.C., April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening.
  • To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches will distribute over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond.
  • Colorectal cancer, which is the third most deadly type of cancer in the U.S., has a disproportionate impact on the Black community, according to the American Cancer Society .
  • Access to regular screening for chronic diseases like colorectal cancer is essential for improving quality of life."

LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 25, 2023

Retrieved on: 
금요일, 3월 31, 2023
Webcast, LH, PIN, NYSE, Labcorp

BURLINGTON, N.C., March 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2023 before the market opens on Tuesday, April 25, 2023.

Key Points: 
  • BURLINGTON, N.C., March 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the first quarter of 2023 before the market opens on Tuesday, April 25, 2023.
  • The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website .
  • The call will be webcast live on the Labcorp Investor Relations website .
  • To access the webcast recording, visit the Labcorp Investor Relations website .

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

Retrieved on: 
목요일, 3월 16, 2023
LH, Health, Drug discovery, Sale, McDermott Will & Emery, NYSE, Antibody, Protein, Patient, Hart–Scott–Rodino Antitrust Improvements Act, ENZ, Securities and Exchange Commission of Pakistan, Jefferies Group, Security (finance), Fine chemical, Nursing, Labcorp, Enzo

FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs). The transaction between two leading global life sciences companies follows several steps initiated by Enzo in 2022 to advance the company’s “focused return” initiative to maximize shareholder value.

Key Points: 
  • FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs).
  • “Completion of the sale will position Enzo to assess and execute on further actions to increase shareholder value and advance our global leadership within the life sciences sector,” said Hamid Erfanian, CEO of Enzo Biochem.
  • “We are very grateful to all our colleagues who have made Enzo Clinical Labs a trusted source for patient care.
  • Enzo Life Sciences’ products including antibodies, genomic probes, assays, biochemicals, and proteins are sold globally to the life sciences market.

Electra Updates Mineral Resource Estimate at its Iron Creek Cobalt-Copper Project in Idaho

Retrieved on: 
금요일, 3월 10, 2023
Technology, Alternative Vehicles, Fuels, EV, Electric Vehicles, Automotive, Alternative Energy, Energy, Other Natural Resources, Batteries, Natural Resources, Table, Technical report, Person, US, CAS, NSR, Mineral Resources Limited, Geology, MMSA, Mining, Cobalt, Electra, ID2, Technical Report Archive & Image Library, LH, Copper, MRE, G&A, Database, Security (finance), Beauty salon, Rare-earth element, Uranium mining, Road, Inference, Indication (medicine), Leapfrog

The 2023 MRE follows the 2014 CIM Definition Standards on Mineral Resources and Mineral Reserves.

Key Points: 
  • The 2023 MRE follows the 2014 CIM Definition Standards on Mineral Resources and Mineral Reserves.
  • These mineral resources are not mineral reserves, because they do not have demonstrated economic viability.
  • Electra retained InnovExplo Inc. (“InnovExplo”) to prepare an updated mineral resource estimate for the Iron Creek project and a supporting technical report.
  • It represents an update of the previous mineral resource estimate contained in the technical report titled “Technical Report with Updated Estimate of Mineral Resources for the Iron Creek project dated November 27, 2019 with an effective date of November 27, 2019, published by Steven J. Ristorcelli, C.P.G., P.G.

Good Clean Love® Launches Pre-Conception Kit to Help Millions of Women Along Their Fertility Journey

Retrieved on: 
화요일, 2월 21, 2023
TTC, Life, Woman, Fertility, Magnesium, Lactic acid, Aloe vera, Vagina, Bacterial vaginosis, Probiotic, Ovulation, Ovary, Health, BV, Vaginal lubrication, Paraben, Movement, Immune system, FDA, MPH, Bacteria, Research, Irritation, LH, Environment, Calcium, Generator, Birth control, Balance, MD

EUGENE, Ore., Feb. 21, 2023 /PRNewswire-PRWeb/ -- Good Clean Love, the gynecologist-recommended natural sexual health and wellness brand supporting women's reproductive health and rights, today announces the launch of its Pre-TTC (Trying To Conceive) Kit in collaboration with The Egg Whisperer, Dr. Aimee. The pre-conception kit includes a variety of products that help make baby-making enjoyable and improve the vaginal biome. The sperm-friendly lube, BioGenesis, has been described as "the best ever" and in side-to-side comparisons with other lubes performs better than others on the market because it does not inhibit sperm mobility, is paraben free and includes calcium and magnesium ions.

Key Points: 
  • The pre-conception kit includes a variety of products that help make baby-making enjoyable and improve the vaginal biome.
  • The fertility journey is hard - about one in five women in the United States suffer from fertility issues.
  • Good Clean Love's Pre-TTC Kit aims to change that.
  • BioGenesis is the first fertility-friendly intimacy gel that's both paraben-free and includes magnesium and calcium ions to support your fertility journey.